FAKTOR-OPTIONSSCHEIN - MORPHOSYS Stock

Certificat

DE000MD3Y089

Market Closed - Börse Stuttgart 12:13:12 2024-06-03 pm EDT
1.27 EUR 0.00% Intraday chart for FAKTOR-OPTIONSSCHEIN - MORPHOSYS
1 month+5.83%
3 months+9.48%
Date Price Change
24-06-03 1.27 0.00%
24-05-31 1.27 +0.79%
24-05-30 1.26 0.00%
24-05-29 1.26 0.00%
24-05-28 1.26 0.00%

Delayed Quote Börse Stuttgart

Last update June 03, 2024 at 12:13 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying MORPHOSYS AG
Issuer Morgan Stanley
WKN MD3Y08
ISINDE000MD3Y089
Date issued 2022-04-28
Strike 45.79
Maturity Unlimited
Parity 17.41 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.94
Lowest since issue 0.052

Company Profile

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Sector
-
More about the company

Ratings for MorphoSys AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: MorphoSys AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.65 EUR
Average target price
58.71 EUR
Spread / Average Target
-14.47%
Consensus